---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-311251"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T13:56:36.921542+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio reports Phase 1b data: ABI-1179 98% HSV-2 shedding reduction, ABI-5366 monthly 76%

## Summary
- ABI-1179 50 mg weekly: 98% HSV-2 shedding reduction (p<0.01), exceeds 80-85% target; 91% lesion reduction (p<0.01).
- ABI-1179: >99% reduction in high viral load shedding, a transmission surrogate.
- ABI-5366 monthly dose: 76% HSV-2 shedding reduction (p<0.01), 88% lesion reduction (p=0.01), 81% high viral load reduction.
- ABI-5366 weekly 350 mg confirmed: 94% shedding, 97% lesion reduction vs placebo.
- Both candidates well-tolerated; Phase 2 planning for ABI-1179 and ABI-5366 weekly; monthly optimization ongoing.

## SEC filing metadata
- accession: 0001193125-25-311251
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000119312525311251/0001193125-25-311251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000119312525311251/asmb-20251208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-311251
- JSON: https://secwatch.observer/filing/0001193125-25-311251.json
- Plain text: https://secwatch.observer/filing/0001193125-25-311251.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.